Asia Pacific Stool Diagnostic Market
Taille du marché en milliards USD
TCAC :
% 
 Période de prévision |
2024 –2030 |
 Taille du marché (année de référence) |
|
 Taille du marché (année de prévision) |
Dollars américains 452,156.67 |
 TCAC |
% |
| Principaux acteurs du marché |
Marché du diagnostic des selles en Asie-Pacifique, par type de test ( test de sang occulte dans les selles , test de biomarqueurs fécaux, tests d'agents pathogènes, test d'antigène des selles, test d'élastase fécale, test de microscopie et autres tests), type de produit (instruments et réactifs), mode (tests en laboratoire et tests au point de service), application (syndrome du côlon irritable, colite ulcéreuse, maladie de Crohn, cancer, diarrhée, hémorroïdes et autres), utilisateur final (hôpitaux, centres de diagnostic, laboratoires, cliniques spécialisées, établissements universitaires et centres de recherche, et autres), canal de distribution (appel d'offres direct, ventes au détail, ventes en ligne et autres) - Tendances et prévisions de l'industrie jusqu'en 2030.
Analyse et perspectives du marché du diagnostic des selles en Asie-Pacifique
La sensibilisation croissante au diagnostic des selles a accru la demande sur le marché. L'augmentation des dépenses de santé pour de meilleurs services de santé contribue également à la croissance du marché, les principaux acteurs du marché se concentrant sur divers lancements et approbations de services pendant cette période cruciale. En outre, l'amélioration des processus et des techniques contribue également à la demande croissante de diagnostics des selles.
Le marché du diagnostic des selles en Asie-Pacifique devrait croître au cours de l'année de prévision en raison de l'augmentation du nombre d'acteurs du marché et de la disponibilité de produits et services avancés. Parallèlement à cela, les fabricants sont également engagés dans l'activité de développement pour lancer de nouveaux services et un diagnostic des selles efficace et précis sur le marché.
L'augmentation des dépenses de santé consacrées au développement et à l'amélioration des produits devrait ouvrir des opportunités au marché. Cependant, le coût élevé des tests pourrait freiner la croissance du marché.
Data Bridge Market Research analyse que le marché du diagnostic des selles en Asie-Pacifique devrait atteindre 452 156,67 milliers USD d'ici 2030, à un TCAC de 7,1 % au cours de la période de prévision.
|
Rapport métrique |
Détails |
|
Période de prévision |
2023 à 2030 |
|
Année de base |
2022 |
|
Années historiques |
2021 (personnalisable de 2015 à 2020) |
|
Unités quantitatives |
Chiffre d'affaires en millions USD, prix en USD |
|
Segments couverts |
Par type de test (test de sang occulte dans les selles, test de biomarqueurs fécaux, tests d'agents pathogènes, test d'antigènes dans les selles, test d'élastase fécale, test de microscopie et autres tests), type de produit (instruments et réactifs), mode (tests en laboratoire et tests au point de service), application (syndrome du côlon irritable, colite ulcéreuse, maladie de Crohn, cancer, diarrhée, hémorroïdes et autres), utilisateur final (hôpitaux, centres de diagnostic, laboratoires, cliniques spécialisées, établissements universitaires et centres de recherche, et autres), canal de distribution (appel d'offres direct, ventes au détail, ventes en ligne et autres) |
|
Pays couverts |
Japon, Chine, Corée du Sud, Inde, Singapour, Thaïlande, Indonésie, Malaisie, Philippines, Australie, Nouvelle-Zélande, Vietnam, Taïwan, Brunei, Népal, Bangladesh, Sri Lanka, Pakistan, Hong Kong, Maldives, Mongolie, Cambodge, Laos et reste de l'Asie-Pacifique |
|
Acteurs du marché couverts |
Some major companies dealing in the Asia-Pacific stool diagnostic market are Abbott, Meridian Bioscience Inc., BIOMERIEUX, Beckman Coulter, Inc. (Subsidiary of Danaher), DiaSorin S.p.A., Runmei, Molbio Diagnostics Pvt. Ltd., Quidel Corporation, Prenetics Limited, Sekisui Diagnostics (A Part of SEKISUI Chemical Co. Ltd.), BioVendor Group, LifeSign LLC, Alfa Scientific Designs, Inc., Eiken Chemical Co., Ltd., SD Biosensor, INC., Cenogenics Corporation, TransGen Biotech Co., Ltd., AdvaCare Pharma, Kibion GmbH, and Beijing Huagen Anbang Technology Co., Ltd. among others. |
Asia-Pacific Stool Diagnostic Market Definition
Stool diagnostic is a series of tests performed on a stool (feces) sample to help diagnose certain digestive tract conditions. Some of these conditions include infection (from parasites, viruses, or bacteria), poor nutrient absorption, and cancer. Microscopic examination and chemical, immunologic, and microbiologic tests are all part of a stool analysis. Leukocytes, occult blood, fat, sugars (reducing substances), pH, pancreatic enzymes, alpha-1 antitrypsin, calprotectin, and infectious causes can all be detected in stool samples with the help of stool diagnosis.
Stool tests can help determine whether or not a bacteria or other microorganism has infected the intestines. However, not all microorganisms in the gut are harmful; in fact, some are required for normal digestion. When harmful bacteria or parasites infect the intestines, they cause bloody diarrhea, and stool diagnosis aid in determining the source of this condition.
Asia-Pacific Stool Diagnostic Market Dynamics
This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:
Driver
- INCREASE IN THE PREVALENCE OF GASTROINTESTINAL DISEASE
The increasing prevalence of gastrointestinal diseases is driving the demand for stool diagnosis. Gastrointestinal diseases can cause many symptoms, including diarrhea, constipation, abdominal pain, and nausea. Various conditions, including infections, and inflammatory bowel disease, can cause these symptoms.
In addition to the growing demand for stool diagnosis for gastrointestinal diseases, there is increasing interest in using stool tests to monitor the microbiome. The microbiome refers to the community of microorganisms that live in the gut and play an important role in digestive and overall health. Stool tests can provide information about the composition and function of the microbiome, which can be useful for identifying dysbiosis (an imbalance in the microbiome) and guiding interventions to improve gut health.
The growing use of non-invasive stool tests for screening and monitoring the microbiome can potentially improve patient outcomes and reduce the burden of gastrointestinal diseases. Thus, the increasing prevalence of gastrointestinal diseases drives the demand for stool diagnosis, particularly in Asia-Pacific.
Restraint
- STRICT GOVERNMENT REGULATIONS
The use of various testing kits across the Asia-Pacific is rapidly increasing. With the increasing prevalence of various gastrointestinal diseases and cancers, there is a need for timely diagnosis and treatment. At the same time, the manufacturers in the market must follow certain regulations to get approval from the upper authorities for launching the product. These stringent guidelines need to be followed; this is one of the most difficult tasks of all the steps.
The increased prevalence of various diseases surged the demand for treatment options amongst the population. However, the uncertainty and risks involved with these stool diagnostics result in stringent and complex regulatory landscapes. As this method of clearance of the products is rigorous and time-consuming, products find it difficult to get approved due to not complying with the regulations. Therefore, the stringent rules and regulations for product approval restrain the growth of the Asia-Pacific stool diagnostic market.
Opportunity
ADVANCEMENTS IN SAMPLE COLLECTION AND HANDLING FOR STOOL DIAGNOSTICS
Advancements in sample collection and handling have played a crucial role in improving the accuracy and reliability of stool diagnostics. Traditional stool diagnostic tests require patients to collect and handle their stool samples, which could be inconvenient and unpleasant. However, advances in sample collection and handling technologies have made stool diagnostics more patient-friendly, efficient, and accurate.
Thus, advancements have made stool diagnostics more accessible and efficient, allowing for earlier detection and treatment of gastrointestinal disorders. As technology advances, we can expect more advancements in sample collection and handling to benefit the field of stool diagnostics. Thus, advancements in sample collection and handling provide an opportunity to improve the process's accuracy, reliability, and patient friendliness.
Challenge
LACK OF SKILLED AND CERTIFIED PROFESSIONALS
The requirement for skilled and certified professionals is a big challenge for stool diagnosis. The demand for stool diagnosis is increased due to increased gastrointestinal disease and colorectal cancer cases in Asia-Pacific. Still, the fewer skilled professionals in the diagnostic center are hampering the market's growth.
A stool diagnosis is a dynamic component in today's difficult time, providing patients with essential information for diagnosing, preventing, treating, and managing their disease and cancer. The requirement for trained staff is a big issue for the Asia-Pacific stool diagnostic market. Due to the lack of skilled and certified professionals, end users cannot install advanced products for stool diagnosis; this may challenge the growth of the Asia-Pacific stool diagnostic market.
Post-Covid-19 Impact Analysis on Asia-Pacific Stool Diagnostic Market
Covid-19 made a massive dent in the diagnostics sector, with a steep fall in patient volumes since the beginning of 2020. The pandemic developed an eerie sense of fear among people, which eventually impacted hospital/clinic and lab visits. Regular checkups became cumbersome, stressful, and time-consuming. While the overall diagnostics sector seemed to have suffered a decline, the area of home diagnostics was the silver lining in the new scheme of things.
Recent Developments
- In June 2022, Prenetics Limited (Nasdaq: PRE) announced the introduction of a novel, non-invasive stool DNA at-home screening test named ColoClear by Circle (ColoClear) for detecting early detection signs of colorectal cancer. This product launch helped the company in its product portfolio expansion
- In June 2022, Meridian Bioscience, Inc. announced the launch of two new sample-specific master mixes, Lyo-Ready Direct DNA qPCR Stool Mix and Lyo-Ready Direct RNA/DNA qPCR Stool Mix. These innovative master mixes improve DNA and RNA molecular detection from crude fecal specimens while allowing room temperature stabilization of diagnostic assays. This product launch helped the company in its product portfolio expansion
Asia-Pacific Stool Diagnostic Market Scope
Asia-Pacific stool diagnostic market is segmented into six notable segments such as test type, product type, mode, application, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
ASIA-PACIFIC STOOL DIAGNOSTIC MARKET, BY TEST TYPE
- Fecal Occult Blood Test
- Fecal Biomarkers Test
- Pathogen Tests
- Stool Antigen Test
- Fecal Elastase Test
- Microscopy Test
- Other Tests
On the basis of test type, the Asia-Pacific stool diagnostic market is segmented into fecal occult blood test, fecal biomarker test, pathogen tests, stool antigen test, fecal elastase test, microscopy test, and other tests.
ASIA-PACIFIC STOOL DIAGNOSTIC MARKET, BY PRODUCT TYPE
- Instruments
- Reagents
On the basis of product type, the Asia-Pacific stool diagnostic market is segmented into instruments and reagents.
ASIA-PACIFIC STOOL DIAGNOSTIC MARKET, BY MODE
- Laboratory Based Testing
- Point Of Care Testing
On the basis of mode, the Asia-Pacific stool diagnostic market is segmented into laboratories based testing and point of care testing.
ASIA-PACIFIC STOOL DIAGNOSTIC MARKET, BY APPLICATION
- Irritable Bowel Syndrome
- Ulcerative Colitis
- Crohn's Disease
- Cancer
- Diarrhea
- Hemorrhoids
- Others
On the basis of application, the Asia-Pacific stool diagnostic market is segmented into irritable bowel syndrome, ulcerative colitis, crohn's disease, cancer, diarrhea, hemorrhoids, and others.
ASIA-PACIFIC STOOL DIAGNOSTIC MARKET, BY END USER
- Hospitals
- Diagnostic Centres
- Laboratory
- Specialty Clinics
- Academic Institutions And Research Centres
- Others
On the basis of end user, the Asia-Pacific stool diagnostic market is segmented into hospitals, diagnostic centers, laboratory, specialty clinics, academic institutions and research centers, and others.
ASIA-PACIFIC STOOL DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL
- Direct Tenders
- Retail Sales
- Online Sales
- Others
On the basis of distribution channel, the Asia-Pacific stool diagnostic market is segmented into direct tenders, retail sales, online sales, and others.
Asia-Pacific Stool Diagnostic Market Regional Analysis/Insights
Asia-Pacific stool diagnostic market is categorized into six notable segments: test type, product type, mode, application, end user, and distribution channel.
The countries covered in this market report are Japan, China, South Korea, India, Singapore, Thailand, Indonesia, Malaysia, Philippines, Australia, New Zealand, Vietnam, Taiwan, Brunei, Nepal, Bangladesh, Sri Lanka, Pakistan, Hong Kong, Maldives, Mongolia, Cambodia, Laos, and rest of Asia-Pacific.
China is expected to dominate Asia-Pacific due to increasing customer inclinations towards advanced technological processes.
The country section of the report also provides individual market-impacting factors and domestic regulation changes that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Asia-Pacific brands and their challenges due to large or scarce competition from local and domestic brands and the impact of sales channels are considered while providing forecast analysis of the country data.
Competitive Landscape and Asia-Pacific Stool Diagnostic Market Share Analysis
Asia-Pacific stool diagnostic market competitive landscape provides details by a competitor. Details included are company overview, company financials, revenue generated, market potential, investment in R&D, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product approvals, product width and breadth, application dominance, and product type lifeline curve. The above data points only relate to the company's focus on the Asia-Pacific stool diagnostic market.
Some major companies dealing in the Asia-Pacific stool diagnostic market are Abbott, Meridian Bioscience Inc., BIOMERIEUX, Beckman Coulter, Inc. (Subsidiary of Danaher), DiaSorin S.p.A., Runmei, Molbio Diagnostics Pvt. Ltd., Quidel Corporation, Prenetics Limited, Sekisui Diagnostics (A Part of SEKISUI Chemical Co. Ltd.), BioVendor Group, LifeSign LLC, Alfa Scientific Designs, Inc., Eiken Chemical Co., Ltd., SD Biosensor, INC., Cenogenics Corporation, TransGen Biotech Co., Ltd., AdvaCare Pharma, Kibion GmbH, and Beijing Huagen Anbang Technology Co., Ltd. among others.
SKU-
Accédez en ligne au rapport sur le premier cloud mondial de veille économique
- Tableau de bord d'analyse de données interactif
- Tableau de bord d'analyse d'entreprise pour les opportunités à fort potentiel de croissance
- Accès d'analyste de recherche pour la personnalisation et les requêtes
- Analyse de la concurrence avec tableau de bord interactif
- Dernières actualités, mises à jour et analyse des tendances
- Exploitez la puissance de l'analyse comparative pour un suivi complet de la concurrence
Table des matières
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE ASIA-PACIFIC STOOL DIAGNOSTIC MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 TEST TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET APPLICATION COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER’S FIVE FORCES
5 INDUSTRY INSIGHTS
6 REGULATIONS
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 INCREASING PREVALENCE OF GASTROINTESTINAL DISEASE
7.1.2 INCREASING PREVALENCE OF ESOPHAGEAL, COLORECTAL, AND GASTRIC CANCERS
7.1.3 RISING DEMAND FOR EARLY DISEASE DIAGNOSIS
7.2 RESTRAINTS
7.2.1 STRICT GOVERNMENT REGULATIONS
7.2.2 HIGH COST ASSOCIATED WITH STOOL DIAGNOSIS
7.3 OPPORTUNITIES
7.3.1 ADVANCEMENTS IN SAMPLE COLLECTION AND HANDLING FOR STOOL DIAGNOSTICS
7.3.2 RISING DEMAND FOR NON-INVASIVE OR MINIMAL INVASIVE STOOL DIAGNOSTICS
7.4 CHALLENGES
7.4.1 LACK OF SKILLED & CERTIFIED PROFESSIONALS
7.4.2 LACK OF STANDARDIZATION IN STOOL DIAGNOSTIC PROCEDURE
8 ASIA-PACIFIC STOOL DIAGNOSTIC MARKET, BY TEST TYPE
8.1 OVERVIEW
8.2 PATHOGEN TEST
8.2.1 H. PYLORI TEST
8.2.1.1 H. PYLORI ANTIGEN TEST
8.2.1.2 UREA BREATH TEST
8.2.2 C. DEFFCILE TEST
8.2.3 OVA & PARASITE TEST
8.2.4 ROTAVIRUS TEST
8.2.5 ADENOVIRUS TEST
8.2.6 SALMONELLA CULTURE TEST
8.2.7 CAMPYLOBACTER TEST
8.2.8 EHEC TEST
8.2.9 OTHERS
8.3 FECAL OCCULT BLOOD TEST
8.3.1 LATERAL FLOW IMMUNO-FOB TEST
8.3.2 IMMUNO-FOB AGGLUTINATION TEST
8.3.3 GUAIC FOB STOOL TEST
8.3.4 OTHERS
8.4 FECAL BIOMARKERS TEST
8.4.1 INFLAMMATORY BIOMARKERS TEST
8.4.1.1 FECAL CALPROTECTIN
8.4.1.2 FECAL LACTOFERRIN
8.4.1.3 OTHERS
8.4.2 CANCER BIOMARKERS TEST
8.4.2.1 COLOGUARD
8.4.2.2 M2 PK STOOL TEST
8.4.2.3 OTHERS
8.4.3 OTHERS
8.5 MICROSCOPY TEST
8.6 STOOL ANTIGEN TEST
8.7 FECAL ELASTASE TEST
8.8 OTHER TESTS
9 ASIA-PACIFIC STOOL DIAGNOSTIC MARKET, BY PRODUCT TYPE
9.1 OVERVIEW
9.2 REAGENTS
9.2.1 FECAL FLOAT SOLUTIONS
9.2.2 BUFFER SOLUTIONS
9.2.3 ABSOLUTE METHANOL
9.2.4 ACID ALCOHOL
9.2.5 OTHERS
9.3 INSTRUMENTS
9.3.1 FECALYZERS
9.3.2 DIGITAL SCALES
9.3.3 MICROSCOPES
9.3.4 MICROSCOPE SLIDES
9.3.5 MICROSCOPE COVER SLIPS
9.3.6 OTHERS
10 ASIA-PACIFIC STOOL DIAGNOSTIC MARKET, BY MODE
10.1 OVERVIEW
10.2 LABORATORY BASED TESTING
10.3 POINT OF CARE TESTING
11 ASIA-PACIFIC STOOL DIAGNOSTIC MARKET, BY APPLICATION
11.1 OVERVIEW
11.2 DIARRHEA
11.3 IRRITABLE BOWEL SYNDROME
11.4 HEMORRHOIDS
11.5 ULCERATIVE COLITIS
11.6 CANCER
11.6.1 COLORECTAL
11.6.2 COLON
11.6.3 OTHER
11.7 CROHN’S DISEASE
11.8 OTHERS
12 ASIA-PACIFIC STOOL DIAGNOSTIC MARKET, BY END USER
12.1 OVERVIEW
12.2 HOSPITALS
12.3 DIAGNOSTIC CENTERS
12.4 LABORATORIES
12.5 SPECIALTY CLINICS
12.6 ACADEMIC INSTITUTES AND RESEARCH CENTERS
12.7 OTHERS
13 ASIA-PACIFIC STOOL DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL
13.1 OVERVIEW
13.2 DIRECT TENDERS
13.3 RETAIL SALES
13.4 ONLINE SALES
13.5 OTHERS
14 ASIA-PACIFIC STOOL DIAGNOSTIC MARKET BY REGION
14.1 ASIA-PACIFIC
14.1.1 CHINA
14.1.2 JAPAN
14.1.3 INDIA
14.1.4 SOUTH KOREA
14.1.5 AUSTRALIA
14.1.6 MALAYSIA
14.1.7 INDONESIA
14.1.8 PHILIPPINES
14.1.9 THAILAND
14.1.10 NEW ZEALAND
14.1.11 TAIWAN
14.1.12 VIETNAM
14.1.13 HONG KONG
14.1.14 SINGAPORE
14.1.15 PAKISTAN
14.1.16 BANGLADESH
14.1.17 SRI LANKA
14.1.18 CAMBODIA
14.1.19 NEPAL
14.1.20 MONGOLIA
14.1.21 LAOS
14.1.22 MALDIVES
14.1.23 BRUNEI
14.1.24 REST OF ASIA-PACIFIC
15 ASIA-PACIFIC STOOL DIAGNOSTIC MARKET: COMPANY LANDSCAPE
15.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
16 SWOT ANALYSIS
17 COMPANY PROFILE
17.1 EIKEN CHEMICAL CO., LTD.
17.1.1 COMPANY SNAPSHOT
17.1.2 REVENUE ANALYSIS
17.1.3 PRODUCT PORTFOLIO
17.1.4 RECENT DEVELOPMENT
17.2 QUIDEL CORPORATION
17.2.1 COMPANY SNAPSHOT
17.2.2 REVENUE ANALYSIS
17.2.3 PRODUCT PORTFOLIO
17.2.4 RECENT DEVELOPMENTS
17.3 BIOMERIEUX
17.3.1 COMPANY SNAPSHOT
17.3.2 REVENUE ANALYSIS
17.3.3 PRODUCT PORTFOLIO
17.3.4 RECENT DEVELOPMENTS
17.4 SD BIOSENSOR, INC.
17.4.1 COMPANY SNAPSHOT
17.4.2 REVENUE ANALYSIS
17.4.3 PRODUCT PORTFOLIO
17.4.4 RECENT DEVELOPMENTS
17.5 SEKISUI DIAGNOSTICS (A PART OF SEKISUI CHEMICAL CO. LTD.)
17.5.1 COMPANY SNAPSHOT
17.5.2 REVENUE ANALYSIS
17.5.3 PRODUCT PORTFOLIO
17.5.4 RECENT DEVELOPMENTS
17.6 ABBOTT
17.6.1 COMPANY SNAPSHOT
17.6.2 REVENUE ANALYSIS
17.6.3 PRODUCT PORTFOLIO
17.6.4 RECENT DEVELOPMENT
17.7 ADVACARE PHARMA
17.7.1 COMPANY SNAPSHOT
17.7.2 PRODUCT PORTFOLIO
17.7.3 RECENT DEVELOPMENTS
17.8 ALFA SCIENTIFIC DESIGNS, INC.
17.8.1 COMPANY SNAPSHOT
17.8.2 PRODUCT PORTFOLIO
17.8.3 RECENT DEVELOPMENTS
17.9 BECKMAN COULTER, INC. (SUBSIDIARY OF DANAHER)
17.9.1 COMPANY SNAPSHOT
17.9.2 REVENUE ANALYSIS
17.9.3 PRODUCT PORTFOLIO
17.9.4 RECENT DEVELOPMENTS
17.1 BEIJING HUAGEN ANBANG TECHNOLOGY CO., LTD.
17.10.1 COMPANY SNAPSHOT
17.10.2 PRODUCT PORTFOLIO
17.10.3 RECENT DEVELOPMENT
17.11 BIOVENDOR GROUP
17.11.1 COMPANY SNAPSHOT
17.11.2 PRODUCT PORTFOLIO
17.11.3 RECENT DEVELOPMENTS
17.12 CENOGENICS CORPORATION
17.12.1 COMPANY SNAPSHOT
17.12.2 PRODUCT PORTFOLIO
17.12.3 RECENT DEVELOPMENTS
17.13 DIASORIN S.P.A.
17.13.1 COMPANY SNAPSHOT
17.13.2 REVENUE ANALYSIS
17.13.3 PRODUCT PORTFOLIO
17.13.4 RECENT DEVELOPMENT
17.14 KIBION GMBH (A SUBSIDIARY OF OREXO AB)
17.14.1 COMPANY SNAPSHOT
17.14.2 REVENUE ANALYSIS
17.14.3 PRODUCT PORTFOLIO
17.14.4 RECENT DEVELOPMENTS
17.15 LIFESIGN LLC
17.15.1 COMPANY SNAPSHOT
17.15.2 PRODUCT PORTFOLIO
17.15.3 RECENT DEVELOPMENTS
17.16 MERIDIAN BIOSCIENCE INC.
17.16.1 COMPANY SNAPSHOT
17.16.2 REVENUE ANALYSIS
17.16.3 PRODUCT PORTFOLIO
17.16.4 RECENT DEVELOPMENT
17.17 MOLBIO DIAGNOSTICS PVT. LTD.
17.17.1 COMPANY SNAPSHOT
17.17.2 PRODUCT PORTFOLIO
17.17.3 RECENT DEVELOPMENT
17.18 PRENETICS LIMITED
17.18.1 COMPANY SNAPSHOT
17.18.2 REVENUE ANALYSIS
17.18.3 PRODUCT PORTFOLIO
17.18.4 RECENT DEVELOPMENT
17.19 RUNMEI
17.19.1 COMPANY SNAPSHOT
17.19.2 PRODUCT PORTFOLIO
17.19.3 RECENT DEVELOPMENTS
17.2 TRANSGEN BIOTECH CO., LTD.
17.20.1 COMPANY SNAPSHOT
17.20.2 PRODUCT PORTFOLIO
17.20.3 RECENT DEVELOPMENT
18 QUESTIONNAIRE
19 RELATED REPORTS
Liste des tableaux
TABLE 1 ASIA-PACIFIC STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 2 ASIA-PACIFIC PATHOGEN TEST IN STOOL DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 3 ASIA-PACIFIC H. PYLORI TEST IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 4 ASIA-PACIFIC FECAL OCCULT BLOOD TEST IN STOOL DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 5 ASIA-PACIFIC FECAL BIOMARKERS TEST IN STOOL DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 6 ASIA-PACIFIC INFLAMMATORY BIOMARKERS TEST IN STOOL DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 7 ASIA-PACIFIC CANCER BIOMARKERS TEST IN STOOL DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 8 ASIA-PACIFIC STOOL DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 9 ASIA-PACIFIC REAGENTS IN STOOL DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 10 ASIA-PACIFIC INSTRUMENTS IN STOOL DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 11 ASIA-PACIFIC STOOL DIAGNOSTIC MARKET, BY MODE, 2021-2030 (USD THOUSAND)
TABLE 12 ASIA-PACIFIC STOOL DIAGNOSTIC MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 13 ASIA-PACIFIC CANCER IN STOOL DIAGNOSTIC MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 14 ASIA-PACIFIC STOOL DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 15 ASIA-PACIFIC STOOL DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 16 ASIA-PACIFIC STOOL DIAGNOSTIC MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND)
TABLE 17 CHINA STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 18 CHINA PATHOGEN TEST IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 19 CHINA H. PYLORI TEST IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 20 CHINA FECAL OCCULT BLOOD TEST IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 21 CHINA FECAL BIOMARKERS TEST IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 22 CHINA INFLAMMATORY BIOMARKERS TESTS IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 23 CHINA CANCER BIOMARKERS TESTS IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 24 CHINA STOOL DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 25 CHINA REAGENTS IN STOOL DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 26 CHINA INSTRUMENTS IN STOOL DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 27 CHINA STOOL DIAGNOSTIC MARKET, BY MODE, 2021-2030 (USD THOUSAND)
TABLE 28 CHINA STOOL DIAGNOSTIC MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 29 CHINA CANCER IN STOOL DIAGNOSTIC MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 30 CHINA STOOL DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 31 CHINA STOOL DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 32 JAPAN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 33 JAPAN PATHOGEN TEST IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 34 JAPAN H. PYLORI TEST IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 35 JAPAN FECAL OCCULT BLOOD TEST IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 36 JAPAN FECAL BIOMARKERS TEST IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 37 JAPAN INFLAMMATORY BIOMARKERS TESTS IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 38 JAPAN CANCER BIOMARKERS TESTS IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 39 JAPAN STOOL DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 40 JAPAN REAGENTS IN STOOL DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 41 JAPAN INSTRUMENTS IN STOOL DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 42 JAPAN STOOL DIAGNOSTIC MARKET, BY MODE, 2021-2030 (USD THOUSAND)
TABLE 43 JAPAN STOOL DIAGNOSTIC MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 44 JAPAN CANCER IN STOOL DIAGNOSTIC MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 45 JAPAN STOOL DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 46 JAPAN STOOL DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 47 INDIA STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 48 INDIA PATHOGEN TEST IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 49 INDIA H. PYLORI TEST IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 50 INDIA FECAL OCCULT BLOOD TEST IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 51 INDIA FECAL BIOMARKERS TEST IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 52 INDIA INFLAMMATORY BIOMARKERS TESTS IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 53 INDIA CANCER BIOMARKERS TESTS IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 54 INDIA STOOL DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 55 INDIA REAGENTS IN STOOL DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 56 INDIA INSTRUMENTS IN STOOL DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 57 INDIA STOOL DIAGNOSTIC MARKET, BY MODE, 2021-2030 (USD THOUSAND)
TABLE 58 INDIA STOOL DIAGNOSTIC MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 59 INDIA CANCER IN STOOL DIAGNOSTIC MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 60 INDIA STOOL DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 61 INDIA STOOL DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 62 SOUTH KOREA STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 63 SOUTH KOREA PATHOGEN TEST IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 64 SOUTH KOREA H. PYLORI TEST IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 65 SOUTH KOREA FECAL OCCULT BLOOD TEST IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 66 SOUTH KOREA FECAL BIOMARKERS TEST IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 67 SOUTH KOREA INFLAMMATORY BIOMARKERS TESTS IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 68 SOUTH KOREA CANCER BIOMARKERS TESTS IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 69 SOUTH KOREA STOOL DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 70 SOUTH KOREA REAGENTS IN STOOL DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 71 SOUTH KOREA INSTRUMENTS IN STOOL DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 72 SOUTH KOREA STOOL DIAGNOSTIC MARKET, BY MODE, 2021-2030 (USD THOUSAND)
TABLE 73 SOUTH KOREA STOOL DIAGNOSTIC MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 74 SOUTH KOREA CANCER IN STOOL DIAGNOSTIC MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 75 SOUTH KOREA STOOL DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 76 SOUTH KOREA STOOL DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 77 AUSTRALIA STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 78 AUSTRALIA PATHOGEN TEST IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 79 AUSTRALIA H. PYLORI TEST IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 80 AUSTRALIA FECAL OCCULT BLOOD TEST IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 81 AUSTRALIA FECAL BIOMARKERS TEST IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 82 AUSTRALIA INFLAMMATORY BIOMARKERS TESTS IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 83 AUSTRALIA CANCER BIOMARKERS TESTS IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 84 AUSTRALIA STOOL DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 85 AUSTRALIA REAGENTS IN STOOL DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 86 AUSTRALIA INSTRUMENTS IN STOOL DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 87 AUSTRALIA STOOL DIAGNOSTIC MARKET, BY MODE, 2021-2030 (USD THOUSAND)
TABLE 88 AUSTRALIA STOOL DIAGNOSTIC MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 89 AUSTRALIA CANCER IN STOOL DIAGNOSTIC MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 90 AUSTRALIA STOOL DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 91 AUSTRALIA STOOL DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 92 MALAYSIA STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 93 MALAYSIA PATHOGEN TEST IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 94 MALAYSIA H. PYLORI TEST IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 95 MALAYSIA FECAL OCCULT BLOOD TEST IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 96 MALAYSIA FECAL BIOMARKERS TEST IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 97 MALAYSIA INFLAMMATORY BIOMARKERS TESTS IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 98 MALAYSIA CANCER BIOMARKERS TESTS IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 99 MALAYSIA STOOL DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 100 MALAYSIA REAGENTS IN STOOL DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 101 MALAYSIA INSTRUMENTS IN STOOL DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 102 MALAYSIA STOOL DIAGNOSTIC MARKET, BY MODE, 2021-2030 (USD THOUSAND)
TABLE 103 MALAYSIA STOOL DIAGNOSTIC MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 104 MALAYSIA CANCER IN STOOL DIAGNOSTIC MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 105 MALAYSIA STOOL DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 106 MALAYSIA STOOL DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 107 INDONESIA STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 108 INDONESIA PATHOGEN TEST IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 109 INDONESIA H. PYLORI TEST IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 110 INDONESIA FECAL OCCULT BLOOD TEST IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 111 INDONESIA FECAL BIOMARKERS TEST IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 112 INDONESIA INFLAMMATORY BIOMARKERS TESTS IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 113 INDONESIA CANCER BIOMARKERS TESTS IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 114 INDONESIA STOOL DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 115 INDONESIA REAGENTS IN STOOL DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 116 INDONESIA INSTRUMENTS IN STOOL DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 117 INDONESIA STOOL DIAGNOSTIC MARKET, BY MODE, 2021-2030 (USD THOUSAND)
TABLE 118 INDONESIA STOOL DIAGNOSTIC MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 119 INDONESIA CANCER IN STOOL DIAGNOSTIC MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 120 INDONESIA STOOL DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 121 INDONESIA STOOL DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 122 PHILIPPINES STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 123 PHILIPPINES PATHOGEN TEST IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 124 PHILIPPINES H. PYLORI TEST IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 125 PHILIPPINES FECAL OCCULT BLOOD TEST IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 126 PHILIPPINES FECAL BIOMARKERS TEST IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 127 PHILIPPINES INFLAMMATORY BIOMARKERS TESTS IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 128 PHILIPPINES CANCER BIOMARKERS TESTS IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 129 PHILIPPINES STOOL DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 130 PHILIPPINES REAGENTS IN STOOL DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 131 PHILIPPINES INSTRUMENTS IN STOOL DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 132 PHILIPPINES STOOL DIAGNOSTIC MARKET, BY MODE, 2021-2030 (USD THOUSAND)
TABLE 133 PHILIPPINES STOOL DIAGNOSTIC MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 134 PHILIPPINES CANCER IN STOOL DIAGNOSTIC MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 135 PHILIPPINES STOOL DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 136 PHILIPPINES STOOL DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 137 THAILAND STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 138 THAILAND PATHOGEN TEST IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 139 THAILAND H. PYLORI TEST IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 140 THAILAND FECAL OCCULT BLOOD TEST IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 141 THAILAND FECAL BIOMARKERS TEST IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 142 THAILAND INFLAMMATORY BIOMARKERS TESTS IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 143 THAILAND CANCER BIOMARKERS TESTS IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 144 THAILAND STOOL DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 145 THAILAND REAGENTS IN STOOL DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 146 THAILAND INSTRUMENTS IN STOOL DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 147 THAILAND STOOL DIAGNOSTIC MARKET, BY MODE, 2021-2030 (USD THOUSAND)
TABLE 148 THAILAND STOOL DIAGNOSTIC MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 149 THAILAND CANCER IN STOOL DIAGNOSTIC MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 150 THAILAND STOOL DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 151 THAILAND STOOL DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 152 NEW ZEALAND STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 153 NEW ZEALAND PATHOGEN TEST IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 154 NEW ZEALAND H. PYLORI TEST IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 155 NEW ZEALAND FECAL OCCULT BLOOD TEST IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 156 NEW ZEALAND FECAL BIOMARKERS TEST IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 157 NEW ZEALAND INFLAMMATORY BIOMARKERS TESTS IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 158 NEW ZEALAND CANCER BIOMARKERS TESTS IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 159 NEW ZEALAND STOOL DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 160 NEW ZEALAND REAGENTS IN STOOL DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 161 NEW ZEALAND INSTRUMENTS IN STOOL DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 162 NEW ZEALAND STOOL DIAGNOSTIC MARKET, BY MODE, 2021-2030 (USD THOUSAND)
TABLE 163 NEW ZEALAND STOOL DIAGNOSTIC MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 164 NEW ZEALAND CANCER IN STOOL DIAGNOSTIC MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 165 NEW ZEALAND STOOL DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 166 NEW ZEALAND STOOL DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 167 TAIWAN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 168 TAIWAN PATHOGEN TEST IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 169 TAIWAN H. PYLORI TEST IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 170 TAIWAN FECAL OCCULT BLOOD TEST IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 171 TAIWAN FECAL BIOMARKERS TEST IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 172 TAIWAN INFLAMMATORY BIOMARKERS TESTS IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 173 TAIWAN CANCER BIOMARKERS TESTS IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 174 TAIWAN STOOL DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 175 TAIWAN REAGENTS IN STOOL DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 176 TAIWAN INSTRUMENTS IN STOOL DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 177 TAIWAN STOOL DIAGNOSTIC MARKET, BY MODE, 2021-2030 (USD THOUSAND)
TABLE 178 TAIWAN STOOL DIAGNOSTIC MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 179 TAIWAN CANCER IN STOOL DIAGNOSTIC MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 180 TAIWAN STOOL DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 181 TAIWAN STOOL DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 182 VIETNAM STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 183 VIETNAM PATHOGEN TEST IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 184 VIETNAM H. PYLORI TEST IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 185 VIETNAM FECAL OCCULT BLOOD TEST IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 186 VIETNAM FECAL BIOMARKERS TEST IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 187 VIETNAM INFLAMMATORY BIOMARKERS TESTS IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 188 VIETNAM CANCER BIOMARKERS TESTS IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 189 VIETNAM STOOL DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 190 VIETNAM REAGENTS IN STOOL DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 191 VIETNAM INSTRUMENTS IN STOOL DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 192 VIETNAM STOOL DIAGNOSTIC MARKET, BY MODE, 2021-2030 (USD THOUSAND)
TABLE 193 VIETNAM STOOL DIAGNOSTIC MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 194 VIETNAM CANCER IN STOOL DIAGNOSTIC MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 195 VIETNAM STOOL DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 196 VIETNAM STOOL DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 197 HONG KONG STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 198 HONG KONG PATHOGEN TEST IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 199 HONG KONG H. PYLORI TEST IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 200 HONG KONG FECAL OCCULT BLOOD TEST IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 201 HONG KONG FECAL BIOMARKERS TEST IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 202 HONG KONG INFLAMMATORY BIOMARKERS TESTS IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 203 HONG KONG CANCER BIOMARKERS TESTS IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 204 HONG KONG STOOL DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 205 HONG KONG REAGENTS IN STOOL DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 206 HONG KONG INSTRUMENTS IN STOOL DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 207 HONG KONG STOOL DIAGNOSTIC MARKET, BY MODE, 2021-2030 (USD THOUSAND)
TABLE 208 HONG KONG STOOL DIAGNOSTIC MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 209 HONG KONG CANCER IN STOOL DIAGNOSTIC MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 210 HONG KONG STOOL DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 211 HONG KONG STOOL DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 212 SINGAPORE STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 213 SINGAPORE PATHOGEN TEST IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 214 SINGAPORE H. PYLORI TEST IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 215 SINGAPORE FECAL OCCULT BLOOD TEST IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 216 SINGAPORE FECAL BIOMARKERS TEST IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 217 SINGAPORE INFLAMMATORY BIOMARKERS TESTS IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 218 SINGAPORE CANCER BIOMARKERS TESTS IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 219 SINGAPORE STOOL DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 220 SINGAPORE REAGENTS IN STOOL DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 221 SINGAPORE INSTRUMENTS IN STOOL DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 222 SINGAPORE STOOL DIAGNOSTIC MARKET, BY MODE, 2021-2030 (USD THOUSAND)
TABLE 223 SINGAPORE STOOL DIAGNOSTIC MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 224 SINGAPORE CANCER IN STOOL DIAGNOSTIC MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 225 SINGAPORE STOOL DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 226 SINGAPORE STOOL DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 227 PAKISTAN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 228 PAKISTAN PATHOGEN TEST IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 229 PAKISTAN H. PYLORI TEST IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 230 PAKISTAN FECAL OCCULT BLOOD TEST IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 231 PAKISTAN FECAL BIOMARKERS TEST IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 232 PAKISTAN INFLAMMATORY BIOMARKERS TESTS IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 233 PAKISTAN CANCER BIOMARKERS TESTS IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 234 PAKISTAN STOOL DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 235 PAKISTAN REAGENTS IN STOOL DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 236 PAKISTAN INSTRUMENTS IN STOOL DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 237 PAKISTAN STOOL DIAGNOSTIC MARKET, BY MODE, 2021-2030 (USD THOUSAND)
TABLE 238 PAKISTAN STOOL DIAGNOSTIC MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 239 PAKISTAN CANCER IN STOOL DIAGNOSTIC MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 240 PAKISTAN STOOL DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 241 PAKISTAN STOOL DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 242 BANGLADESH STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 243 BANGLADESH PATHOGEN TEST IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 244 BANGLADESH H. PYLORI TEST IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 245 BANGLADESH FECAL OCCULT BLOOD TEST IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 246 BANGLADESH FECAL BIOMARKERS TEST IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 247 BANGLADESH INFLAMMATORY BIOMARKERS TESTS IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 248 BANGLADESH CANCER BIOMARKERS TESTS IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 249 BANGLADESH STOOL DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 250 BANGLADESH REAGENTS IN STOOL DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 251 BANGLADESH INSTRUMENTS IN STOOL DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 252 BANGLADESH STOOL DIAGNOSTIC MARKET, BY MODE, 2021-2030 (USD THOUSAND)
TABLE 253 BANGLADESH STOOL DIAGNOSTIC MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 254 BANGLADESH CANCER IN STOOL DIAGNOSTIC MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 255 BANGLADESH STOOL DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 256 BANGLADESH STOOL DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 257 SRI LANKA STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 258 SRI LANKA PATHOGEN TEST IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 259 SRI LANKA H. PYLORI TEST IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 260 SRI LANKA FECAL OCCULT BLOOD TEST IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 261 SRI LANKA FECAL BIOMARKERS TEST IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 262 SRI LANKA INFLAMMATORY BIOMARKERS TESTS IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 263 SRI LANKA CANCER BIOMARKERS TESTS IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 264 SRI LANKA STOOL DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 265 SRI LANKA REAGENTS IN STOOL DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 266 SRI LANKA INSTRUMENTS IN STOOL DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 267 SRI LANKA STOOL DIAGNOSTIC MARKET, BY MODE, 2021-2030 (USD THOUSAND)
TABLE 268 SRI LANKA STOOL DIAGNOSTIC MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 269 SRI LANKA CANCER IN STOOL DIAGNOSTIC MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 270 SRI LANKA STOOL DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 271 SRI LANKA STOOL DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 272 CAMBODIA STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 273 CAMBODIA PATHOGEN TEST IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 274 CAMBODIA H. PYLORI TEST IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 275 CAMBODIA FECAL OCCULT BLOOD TEST IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 276 CAMBODIA FECAL BIOMARKERS TEST IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 277 CAMBODIA INFLAMMATORY BIOMARKERS TESTS IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 278 CAMBODIA CANCER BIOMARKERS TESTS IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 279 CAMBODIA STOOL DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 280 CAMBODIA REAGENTS IN STOOL DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 281 CAMBODIA INSTRUMENTS IN STOOL DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 282 CAMBODIA STOOL DIAGNOSTIC MARKET, BY MODE, 2021-2030 (USD THOUSAND)
TABLE 283 CAMBODIA STOOL DIAGNOSTIC MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 284 CAMBODIA CANCER IN STOOL DIAGNOSTIC MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 285 CAMBODIA STOOL DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 286 CAMBODIA STOOL DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 287 NEPAL STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 288 NEPAL PATHOGEN TEST IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 289 NEPAL H. PYLORI TEST IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 290 NEPAL FECAL OCCULT BLOOD TEST IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 291 NEPAL FECAL BIOMARKERS TEST IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 292 NEPAL INFLAMMATORY BIOMARKERS TESTS IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 293 NEPAL CANCER BIOMARKERS TESTS IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 294 NEPAL STOOL DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 295 NEPAL REAGENTS IN STOOL DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 296 NEPAL INSTRUMENTS IN STOOL DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 297 NEPAL STOOL DIAGNOSTIC MARKET, BY MODE, 2021-2030 (USD THOUSAND)
TABLE 298 NEPAL STOOL DIAGNOSTIC MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 299 NEPAL CANCER IN STOOL DIAGNOSTIC MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 300 NEPAL STOOL DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 301 NEPAL STOOL DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 302 MONGOLIA STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 303 MONGOLIA PATHOGEN TEST IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 304 MONGOLIA H. PYLORI TEST IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 305 MONGOLIA FECAL OCCULT BLOOD TEST IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 306 MONGOLIA FECAL BIOMARKERS TEST IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 307 MONGOLIA INFLAMMATORY BIOMARKERS TESTS IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 308 MONGOLIA CANCER BIOMARKERS TESTS IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 309 MONGOLIA STOOL DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 310 MONGOLIA REAGENTS IN STOOL DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 311 MONGOLIA INSTRUMENTS IN STOOL DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 312 MONGOLIA STOOL DIAGNOSTIC MARKET, BY MODE, 2021-2030 (USD THOUSAND)
TABLE 313 MONGOLIA STOOL DIAGNOSTIC MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 314 MONGOLIA CANCER IN STOOL DIAGNOSTIC MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 315 MONGOLIA STOOL DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 316 MONGOLIA STOOL DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 317 LAOS STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 318 LAOS PATHOGEN TEST IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 319 LAOS H. PYLORI TEST IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 320 LAOS FECAL OCCULT BLOOD TEST IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 321 LAOS FECAL BIOMARKERS TEST IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 322 LAOS INFLAMMATORY BIOMARKERS TESTS IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 323 LAOS CANCER BIOMARKERS TESTS IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 324 LAOS STOOL DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 325 LAOS REAGENTS IN STOOL DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 326 LAOS INSTRUMENTS IN STOOL DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 327 LAOS STOOL DIAGNOSTIC MARKET, BY MODE, 2021-2030 (USD THOUSAND)
TABLE 328 LAOS STOOL DIAGNOSTIC MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 329 LAOS CANCER IN STOOL DIAGNOSTIC MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 330 LAOS STOOL DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 331 LAOS STOOL DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 332 MALDIVES STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 333 MALDIVES PATHOGEN TEST IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 334 MALDIVES H. PYLORI TEST IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 335 MALDIVES FECAL OCCULT BLOOD TEST IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 336 MALDIVES FECAL BIOMARKERS TEST IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 337 MALDIVES INFLAMMATORY BIOMARKERS TESTS IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 338 MALDIVES CANCER BIOMARKERS TESTS IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 339 MALDIVES STOOL DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 340 MALDIVES REAGENTS IN STOOL DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 341 MALDIVES INSTRUMENTS IN STOOL DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 342 MALDIVES STOOL DIAGNOSTIC MARKET, BY MODE, 2021-2030 (USD THOUSAND)
TABLE 343 MALDIVES STOOL DIAGNOSTIC MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 344 MALDIVES CANCER IN STOOL DIAGNOSTIC MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 345 MALDIVES STOOL DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 346 MALDIVES STOOL DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 347 BRUNEI STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 348 BRUNEI PATHOGEN TEST IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 349 BRUNEI H. PYLORI TEST IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 350 BRUNEI FECAL OCCULT BLOOD TEST IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 351 BRUNEI FECAL BIOMARKERS TEST IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 352 BRUNEI INFLAMMATORY BIOMARKERS TESTS IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 353 BRUNEI CANCER BIOMARKERS TESTS IN STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
TABLE 354 BRUNEI STOOL DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 355 BRUNEI REAGENTS IN STOOL DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 356 BRUNEI INSTRUMENTS IN STOOL DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 357 BRUNEI STOOL DIAGNOSTIC MARKET, BY MODE, 2021-2030 (USD THOUSAND)
TABLE 358 BRUNEI STOOL DIAGNOSTIC MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 359 BRUNEI CANCER IN STOOL DIAGNOSTIC MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 360 BRUNEI STOOL DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 361 BRUNEI STOOL DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 362 REST OF ASIA-PACIFIC STOOL DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD THOUSAND)
Liste des figures
FIGURE 1 ASIA-PACIFIC STOOL DIAGNOSTIC MARKET: SEGMENTATION
FIGURE 2 ASIA-PACIFIC STOOL DIAGNOSTIC MARKET: DATA TRIANGULATION
FIGURE 3 ASIA-PACIFIC STOOL DIAGNOSTIC MARKET: DROC ANALYSIS
FIGURE 4 ASIA-PACIFIC STOOL DIAGNOSTIC MARKET: ASIA-PACIFIC VS COUNTRY MARKET ANALYSIS
FIGURE 5 ASIA-PACIFIC STOOL DIAGNOSTIC MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 ASIA-PACIFIC STOOL DIAGNOSTIC MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 ASIA-PACIFIC STOOL DIAGNOSTIC MARKET: DBMR MARKET POSITION GRID
FIGURE 8 ASIA-PACIFIC STOOL DIAGNOSTIC MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 9 ASIA-PACIFIC STOOL DIAGNOSTIC MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 ASIA-PACIFIC STOOL DIAGNOSTIC MARKET: SEGMENTATION
FIGURE 11 INCREASING PREVALENCE OF GASTROINTESTINAL DIASEASE IS EXPECTED TO DRIVE THE ASIA-PACIFIC STOOL DIAGNOSTIC MARKET IN THE FORECAST PERIOD
FIGURE 12 PATHOGEN TEST SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA-PACIFIC STOOL DIAGNOSTIC MARKET IN 2023 & 2030
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE ASIA-PACIFIC STOOL DIAGNOSTIC MARKET
FIGURE 14 ASIA-PACIFIC STOOL DIAGNOSTIC MARKET: BY TEST TYPE, 2022
FIGURE 15 ASIA-PACIFIC STOOL DIAGNOSTIC MARKET: BY TEST TYPE, 2023-2030 (USD THOUSAND)
FIGURE 16 ASIA-PACIFIC STOOL DIAGNOSTIC MARKET: BY TEST TYPE, CAGR (2023-2030)
FIGURE 17 ASIA-PACIFIC STOOL DIAGNOSTIC MARKET: BY TEST TYPE, LIFELINE CURVE
FIGURE 18 ASIA-PACIFIC STOOL DIAGNOSTIC MARKET: BY PRODUCT TYPE, 2022
FIGURE 19 ASIA-PACIFIC STOOL DIAGNOSTIC MARKET: BY PRODUCT TYPE, 2023-2030 (USD THOUSAND)
FIGURE 20 ASIA-PACIFIC STOOL DIAGNOSTIC MARKET: BY PRODUCT TYPE, CAGR (2023-2030)
FIGURE 21 ASIA-PACIFIC STOOL DIAGNOSTIC MARKET: BY PRODUCT TYPE, LIFELINE CURVE
FIGURE 22 ASIA-PACIFIC STOOL DIAGNOSTIC MARKET: BY MODE, 2022
FIGURE 23 ASIA-PACIFIC STOOL DIAGNOSTIC MARKET: BY MODE, 2023-2030 (USD THOUSAND)
FIGURE 24 ASIA-PACIFIC STOOL DIAGNOSTIC MARKET: BY MODE, CAGR (2023-2030)
FIGURE 25 ASIA-PACIFIC STOOL DIAGNOSTIC MARKET: BY MODE, LIFELINE CURVE
FIGURE 26 ASIA-PACIFIC STOOL DIAGNOSTIC MARKET: BY APPLICATION, 2022
FIGURE 27 ASIA-PACIFIC STOOL DIAGNOSTIC MARKET: BY APPLICATION, 2023-2030 (USD THOUSAND)
FIGURE 28 ASIA-PACIFIC STOOL DIAGNOSTIC MARKET: BY APPLICATION, CAGR (2023-2030)
FIGURE 29 ASIA-PACIFIC STOOL DIAGNOSTIC MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 30 ASIA-PACIFIC STOOL DIAGNOSTIC MARKET: BY END USER, 2022
FIGURE 31 ASIA-PACIFIC STOOL DIAGNOSTIC MARKET: BY END USER, 2023-2030 (USD THOUSAND)
FIGURE 32 ASIA-PACIFIC STOOL DIAGNOSTIC MARKET: BY END USER, CAGR (2023-2030)
FIGURE 33 ASIA-PACIFIC STOOL DIAGNOSTIC MARKET: BY END USER, LIFELINE CURVE
FIGURE 34 ASIA-PACIFIC STOOL DIAGNOSTIC MARKET: BY DISTRIBUTION CHANNEL, 2022
FIGURE 35 ASIA-PACIFIC STOOL DIAGNOSTIC MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD THOUSAND)
FIGURE 36 ASIA-PACIFIC STOOL DIAGNOSTIC MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)
FIGURE 37 ASIA-PACIFIC STOOL DIAGNOSTIC MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 38 ASIA-PACIFIC STOOL DIAGNOSTIC MARKET: SNAPSHOT (2022)
FIGURE 39 ASIA-PACIFIC STOOL DIAGNOSTIC MARKET: BY COUNTRY (2022)
FIGURE 40 ASIA-PACIFIC STOOL DIAGNOSTIC MARKET: BY COUNTRY (2023 & 2030)
FIGURE 41 ASIA-PACIFIC STOOL DIAGNOSTIC MARKET: BY COUNTRY (2022 & 2030)
FIGURE 42 ASIA-PACIFIC STOOL DIAGNOSTIC MARKET: TEST TYPE (2023-2030)
FIGURE 43 ASIA-PACIFIC STOOL DIAGNOSTIC MARKET: COMPANY SHARE 2022 (%)
Méthodologie de recherche
La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. L'étape consiste à obtenir des informations sur le marché ou des données connexes via diverses sources et stratégies. Elle comprend l'examen et la planification à l'avance de toutes les données acquises dans le passé. Elle englobe également l'examen des incohérences d'informations observées dans différentes sources d'informations. Les données de marché sont analysées et estimées à l'aide de modèles statistiques et cohérents de marché. De plus, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. Pour en savoir plus, veuillez demander un appel d'analyste ou déposer votre demande.
La méthodologie de recherche clé utilisée par l'équipe de recherche DBMR est la triangulation des données qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). Les modèles de données incluent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement des entreprises, l'analyse des brevets, l'analyse des prix, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse globale par rapport à l'analyse régionale et des parts des fournisseurs. Pour en savoir plus sur la méthodologie de recherche, envoyez une demande pour parler à nos experts du secteur.
Personnalisation disponible
Data Bridge Market Research est un leader de la recherche formative avancée. Nous sommes fiers de fournir à nos clients existants et nouveaux des données et des analyses qui correspondent à leurs objectifs. Le rapport peut être personnalisé pour inclure une analyse des tendances des prix des marques cibles, une compréhension du marché pour d'autres pays (demandez la liste des pays), des données sur les résultats des essais cliniques, une revue de la littérature, une analyse du marché des produits remis à neuf et de la base de produits. L'analyse du marché des concurrents cibles peut être analysée à partir d'une analyse basée sur la technologie jusqu'à des stratégies de portefeuille de marché. Nous pouvons ajouter autant de concurrents que vous le souhaitez, dans le format et le style de données que vous recherchez. Notre équipe d'analystes peut également vous fournir des données sous forme de fichiers Excel bruts, de tableaux croisés dynamiques (Fact book) ou peut vous aider à créer des présentations à partir des ensembles de données disponibles dans le rapport.
